These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9374154)

  • 81. [Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia].
    Ikeda K; Mita M; Ishibashi T; Shichishima T; Maruyama Y
    Rinsho Ketsueki; 1998 Sep; 39(9):676-9. PubMed ID: 9796402
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Clinical pharmacology of hydroxyurea].
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1995; 26(1):39-45. PubMed ID: 7747561
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].
    Chiba K; Kurosawa M; Kondo T; Suzuki S; Musashi M; Asaka M; Imamura M; Hattori Y; Oba Y
    Rinsho Ketsueki; 2000 Jan; 41(1):61-4. PubMed ID: 10695401
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Ulcers following therapy with hydroxyurea. Three case reports and review of the literature].
    Boneberger S; Rupec RA; Ruzicka T
    Hautarzt; 2010 Jul; 61(7):598-602. PubMed ID: 19763519
    [TBL] [Abstract][Full Text] [Related]  

  • 85. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia.
    Benelux CML Study Group
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S19-20. PubMed ID: 8769694
    [No Abstract]   [Full Text] [Related]  

  • 87. Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding.
    Vomvouras S; Pakula AS; Shaw JM
    J Am Acad Dermatol; 1991 Jun; 24(6 Pt 1):1016-7. PubMed ID: 1869665
    [No Abstract]   [Full Text] [Related]  

  • 88. Gottron's papules-like eruption developing under hydroxyurea therapy.
    Slobodin G; Lurie M; Munichor M; Kovalev J; Rosner I
    Rheumatol Int; 2006 Jun; 26(8):768-70. PubMed ID: 16583187
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia.
    Demirçay Z; Cömert A; Adigüzel C
    Int J Dermatol; 2002 Dec; 41(12):872-4. PubMed ID: 12492973
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
    Wang DP; Liang MY; Zhang XH; Wang SM
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):735-9. PubMed ID: 21176552
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Longitudinal melanonychia and hydroxyurea].
    Pirard C; Michaux JL; Bourlond A
    Ann Dermatol Venereol; 1994; 121(2):106-9. PubMed ID: 7979014
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Ulcerative lichen planus-like dermatitis associated with hydroxyurea.
    Renfro L; Kamino H; Raphael B; Moy J; Sanchez M
    J Am Acad Dermatol; 1991 Jan; 24(1):143-5. PubMed ID: 1825667
    [No Abstract]   [Full Text] [Related]  

  • 93. [Hydroxyurea induced-leg ulcer in polycythemia vera].
    Khaled A; El Guellali N; Aissaoui L; Robbana F; Ezzine N; Fazaa B; Kamoun MR
    Tunis Med; 2011 Mar; 89(3):292-4. PubMed ID: 21387237
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report.
    Patel M; Dukes IA; Hull JC
    Am J Obstet Gynecol; 1991 Sep; 165(3):565-6. PubMed ID: 1892181
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea.
    Shammas F; Meyer P; Heikkila R; Apeland T; Gøransson L; Berland J; Kjellevold K
    Acta Haematol; 1997; 97(3):184-6. PubMed ID: 9066715
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
    Litam PP; Landaw SA; Zamkoff KW
    Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation].
    Salmon-Ehr V; Leborgne G; Vilque JP; Potron G; Bernard P
    Rev Med Interne; 2000 Jan; 21(1):30-4. PubMed ID: 10685452
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Unusual dermatological toxicity of hydroxyurea in two dogs with spontaneously occurring tumours.
    Marconato L; Bonfanti U; Fileccia I
    J Small Anim Pract; 2007 Sep; 48(9):514-7. PubMed ID: 17617162
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Skin lesion caused by hydroxyurea.
    Hirri HM; Green PJ
    Eur J Haematol; 2001; 67(5-6):328-9. PubMed ID: 11872082
    [No Abstract]   [Full Text] [Related]  

  • 100. Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor.
    Stagno F; Guglielmo P; Consoli U; Fiumara P; Russo M; Giustolisi R
    Blood; 1999 Aug; 94(4):1479-80. PubMed ID: 10484634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.